10/575790

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applica	ants:	Colandrea, et al.		
	(3,4-DI	To be assigned  ISUBSTITUTED)PROPANOIC CARBOXYLATES P (EDG) RECEPTOR AGONISTS	Art Unit: _	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Ratents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By \_\_\_\_\_ Date \_\_\_\_

**RELATED APPLICATION** 

**FILING DATE** 

## INFORMATION DISCLOSURE STATEMENT

10/575790

**MERCK CASE** 

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER

months prior to the filing of this Statement.

If th	nis is inconvenient, additional copies will be submitted upon request	•						
(	6. In accordance with 37 C.F.R. 1.97, (check one)							
	the attached information is filed within three months of the filing dat	te of the captioned case.						
	the attached information is filed more than three months after the filing date but prior to the mailing of a first  Office Action on the merits.							
	the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.							
	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).							
	each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.							
	each item of information contained in the information disclosure staffrom a foreign patent office in a counterpart application and this condesignated in §1.56(c) more than thirty days prior to the filing of the	mmunication was not rece	ived by any individual					
	no item of information contained in this Information Disclosure State	ement was cited in a comr	nunication from a					

foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification

after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three

Respectfully submitted,

Punto
By: Raynard Yuro
Attorney For Applicant(s)
Reg. No. <u>45,450</u>
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732)594- <u>0182</u>
Date: April 12, 2006

AP15 RCC (Approved for use Justified Tel/2006 FeNB Resigned) SUBSTITUTE for PTO/SB/08A (07-05); Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

	Substitute for form 44404 (DTO			COMPLETE IF KNOWN			
	Substitute for form 1449A/PTO INFORMATION	l DIS	CLOSURE	Application Number	To be Assigned	10/57579	10
	STATEMENT B	<b>3</b> 7 <b>A</b> TO	DI ICANT	Filing Date			
	STATEMENT	Y AP	PLICANI	First Named Inventor			
	(	4		Group Art Unit			
	(use as many shee	eis as r	necessary)	Examiner Name			
Shee	t 1	of	2	Attorney Docket Number	21419YP		

			U.S. PA	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document  Kind  Code  (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		2004/0224941		Sughrue Mion, PLLC	11/11/2004
		3,258,465		Hoffman-La Roche Inc.	06/28/1966
		2004/0058894		Merck & Co., Inc.	03/25/2004
		6,699,853		Hoechst Schering AgrEvo GmbH	03/02/2004

			FORE	IGN PATENT	T DOCUMENTS	
Examiner	Cite	Foreign Patent Document  Office Number Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
Initials*	No.					
			WO 00/25768		TREGA BIOSCIENCES, INC.	05/11/2000
			WO 97/44333		MERCK & CO., INC.	11/27/1997
			WO 00/47188		EMISPHERE TECHNOLOGIES, INC	. 08/17/2000
			WO 2004/103279		MERCK & CO., INC.	12/02/2004
			WO 2004/058149		Merck & Co., Inc.	04/15/2004
			WO 96/04271		Dr. Karl Thomae GMBH	02/15/1996

Examiner Signature	Date Considered	
	<u> </u>	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.